“The first half of the year was marked by considerable progress across our robust clinical development pipeline as we seek to pioneer a new era in brain diseases,” said Henry Gosebruch, president and chief executive officer, Neumora. “We are excited for the topline data readout from our pivotal Phase 3 KOASTAL-1 study of navacaprant to treat major depressive disorder (MDD), which we continue to expect in the fourth quarter. We are committed to bringing navacaprant to the millions of patients suffering with MDD as expeditiously as possible.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- 3 Best Stocks to Buy Now, 7/23/2024, According to Top Analysts
- Neumora Therapeutics initiated with a Buy at Needham
- Neumora Therapeutics initiated with an Outperform at Mizuho
- Neumora Therapeutics announces initiation of Phase 1b study of NMRA-511